Working with the NHS and other healthcare organisations
We believe together works better. We are part of the NHS team.
The NHS is changing and the needs of our partners and the people they care for reflect this. We believe that through working in partnership, combining our skills, experience and resources, together we can tackle some of the challenges facing the NHS today, united by the common goal of putting patients at the heart of our health service.
Pfizer has a rich heritage of working in the UK. Over the past sixty years, we have discovered and developed medicines which have improved and saved the lives of millions of people across Britain and around the world.
As well as being a leading supplier of medicines to the NHS, we are committed to working with our partners from across the NHS, as well as academia and other healthcare organisations (HCOs), to improve the delivery of healthcare and achieve the best health outcomes for people in the UK.
Our work with the NHS and other healthcare organisations is described below and reported within our 2015 report on payments to healthcare professionals and healthcare organisations.
Joint Working describes situations where, for the benefit of patients, NHS and industry organisations pool skills, experience and/or resources for the joint
development and implementation of patient-centred projects and share a commitment to successful delivery.
Our Joint Working projects with NHS partners around the UK cover health areas including smoking cessation, rheumatology, medicines management and chronic conditions.
Medical and Educational Goods and Services and other types of donations and grants
Medical and Educational Goods and Services (MEGS) are either financial grants, or services delivered by a Pfizer colleague or supplier engaged by Pfizer. MEGS are intended to either enhance patient care or benefit the NHS and maintain patient care. Our involvement is strictly limited to the provision or delivery of the MEGS grant or service and we do not expect to receive any benefit in return. MEGS do not constitute an inducement to prescribe, supply, administer, recommend, buy or sell any medicine.
We are proud to support patients and the NHS through MEGS but we do not proactively share detailed outcomes analyses of these projects; instead, the decision to share more in-depth information is at the discretion of the healthcare organisations themselves.
Through corporate sponsorships, Pfizer provides funding to a third party in support of a project such as meetings, events or publications. Unlike MEGS, corporate sponsorships do allow the sponsoring company to receive some form of benefit such as an opportunity to talk about Pfizer’s products, brands or business interests. For example, we may provide a corporate sponsorship to a healthcare organisation to run a medical meeting and at that meeting, have information available to attendees on one of our projects, services or – where appropriate – medicines.
Details about our corporate sponsorships are captured in our 2015 report on payments to healthcare professionals and healthcare organisations.
PP-PFE-GBR-0147/Date of preparation: June 2016